Nafamostat Undergoing Clinical Trials After Curing Coronavirus Patients - (The Korea Bizwire via NewsPoints Desk)

  • Study findings published in the International Journal of Infectious Diseases suggest nafamostat, a drug used to treat acute pancreatitis and prevent blood clotting for patients receiving blood dialysis, was found to be effective against COVID-19, reported The Korea Bizwire.

  • The paper explained that an experiment on three severe coronavirus patients over 65 years of age requiring oxygen treatment revealed that nafamostat was effective against COVID-19 and related inflammation.

  • Prior to the nafamostat clinical trials, they were treated with the anti-HIV drug Kaletra and the anti-malarial chloroquine.

  • The medical team gave the COVID-19 patients a dose of nafamostat 200 mg every day, after which patients were able to breathe on their own, with inflammation subsiding.

  • SK Chemicals Co., an affiliate of South Korean conglomerate SK Group, currently sells nafamostat, which was developed by Torii Pharmaceutical, under the brand name Futan.

  • Meanwhile, Chong Kun Dang Pharmaceutical is currently discussing plans to request emergency use of napabeltan, that company's generic version of nafamostat.

To read more NewsPoints articles, click here.